ArticleFrontiers in medicine2025
Development and validation of a nomogram to predict atelectasis in adult lymph node fistula tracheobronchial tuberculosis patients.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node fistula tracheobronchial tuberculosis (TBTB) is a severe respiratory condition that can result in complications such as airway stenosis and atelectasis, posing significant clinical challenges, particularly in adults. Currently, no standardized assessment tools are available to predict the risk of atelectasis in these patients, highlighting the need to develop an effective predictive model to guide early clinical intervention and personalized treatment. Methods: A retrospective study was conducted involving 547 adult patients diagnosed with lymph node fistula TBTB at our hospital between January 2017 and December 2023. Diagnoses were confirmed by chest computed tomography, bronchoscopy, and combined etiological or pathological examinations. After applying the inclusion and exclusion criteria, 301 cases were included in the final analysis. Patients were randomly assigned to a development group ( Results: Among the 301 patients with lymph node fistula TBTB, the incidence of atelectasis was 60.13% (181/301). Of those, 72.93% (132/181) had right lung involvement, and 50.28% (91/181) specifically had atelectasis in the right middle lobe. Independent predictors identified by multivariable logistic regression included age, occupation as a farmer, mediastinal lymphadenopathy with ring enhancement, and right middle lobe bronchial involvement. A risk nomogram was developed using these predictors. The area under the curve (AUC) of the nomogram was 0.824 (95% CI: 0.685-0.806) in the development group and 0.857 (95% CI: 0.702-0.877) in the validation group. Calibration plots based on 500 bootstrap resamples showed good agreement between predicted and observed probabilities across both groups. DCA revealed that the model provided a net clinical benefit within threshold probability ranges of 0.2-0.9 for the development group and 0.15-0.85 for the validation group. Conclusion: The predictive model and associated nomogram developed in this study can accurately estimate the risk of atelectasis in adult patients with lymph node fistula TBTB. This tool may assist clinicians in developing individualized intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.